This site is intended for healthcare professionals only

DiabetesontheNet Logo
×


Diabetes Digest

Issue:

Early View

Share this article
Share on facebook
Share on twitter
Share on email
Share on print

Hybrid closed-loop more effective than sensor-augmented pump

Devices – October 2019 digest

Cambridge study finds insulin delivery via a hybrid closed-loop system improves glycaemic control while reducing the risk of hypoglycaemia in type 1 diabetes.

Insulin delivery via a hybrid closed-loop system (CLS) improves glycaemic control while reducing the risk of hypoglycaemia in type 1 diabetes, according to the results of the largest study of this technology in outpatients to date. There was significantly greater time-in-range and significantly lower HbA1c with the hybrid CLS than with sensor-augmented pumps in people with suboptimally-controlled type 1 diabetes at 12 weeks. 

According to Dr Martin Tauschmann, who presented the results of the Cambridge hybrid closed-loop study at EASD, participants using the technology spent an average of 3 additional hours within target range compared to an extra 29 minutes in those using sensor-augmented pumps. A similar drop in the amount of time spent in hyperglycaemia each day was found for each of the two groups: 2.9 hours with hybrid CLS versus 29 minutes with a sensor-augmented pump. There was a between-group difference of 0.5 mmol/L (0.5%) in HbA1c readings, with the use of hybrid CLS resulting in a 0.6 mmol/L (0.6%) reduction in HbA1c. In addition to this, greater improvements were found in average blood glucose with hybrid CLS. However, the time spent in hypoglycaemia was similar in both groups and there was no difference in total daily insulin dose or bodyweight.

The home-based adults, adolescents and children aged at least 6 years had an average HbA1c of 66–67 mmol/mol (8.2–8.3%) at the start of the study. Forty-six were randomly assigned to hybrid closed-loop therapy and 40 to sensor-augmented pump therapy, with a primary endpoint of time within target range (3.9–10.0 mmol/L) 12 weeks after randomisation to a treatment arm. The hybrid CLS consisted of an Android phone using Cambridge model predictive control algorithm to predict future glucose levels along with the Medtronic MiniMed 640G and Enlite 3 sensor.

Share this article
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on whatsapp
For the latest news and articles

Sign up to all DiabetesontheNet journals

© Copyright Omniamed Communications. All Rights Reserved​
108 Cannon Street, London, EC4N 6EU. Registered in the United Kingdom​
Omniamed logo white
DiabetesontheNet Logo
For the latest news and articles

Sign up to all DiabetesontheNet journals

 

By clicking ‘Subscribe’, you are agreeing that DiabetesontheNet.com are able to email you periodic newsletters. You may unsubscribe from these at any time. Your info is safe with us and we will never sell or trade your details. For information please review our Privacy Policy.

DiabetesontheNet Logo

This website is for healthcare professionals only. To continue, please confirm that you are a healthcare professional below.